Yongan Pharmaceutical (002365.SZ): Net profit of 28.68 million yuan in the first quarter increased 91.42% year-on-year

On April 29, Ge Longhui | Yongan Pharmaceutical (002365.SZ) released its first quarter report. Operating revenue was 197 million yuan, down 36.80% year on year, net profit of 28.68 million yuan, up 91.42% year on year, after deducting non-net profit of 1997 million yuan, up 247.61% year on year, with basic earnings of 0.0973 yuan per share.

Gelonghui FinanceApr 29 21:16

Express News | Yongan Pharmaceutical: Plans to repurchase shares between 40 million yuan and 80 million yuan

BreakingsApr 29 20:08

Yongan Pharmaceutical (002365.SZ) has been re-certified as a high-tech enterprise

Gelonghui, April 23 | Yongan Pharmaceutical (002365.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Hubei Provincial Department of Science and Technology, the Hubei Provincial Department of Finance, and the Hubei Provincial Taxation Bureau of the State Administration of Taxation, and the company passed the new certification as a high-tech enterprise. The certificate number is GR202342010015, the date of issue is October 26, 2023, and is valid for three years.

Gelonghui FinanceApr 23 15:40

Yongan Pharmaceutical (002365.SZ) announced its 2023 annual results, changing from profit to loss of RMB 12.312,600

Yongan Pharmaceutical (002365.SZ) released its 2023 annual report. During the reporting period, the company achieved an operating income of 9...

Zhitong FinanceApr 18 21:23

Express News | Yongan Pharmaceutical: Snow damage to several of the company's buildings has not had a significant impact on operations

BreakingsFeb 29 19:24

Yongan Pharmaceutical (002365.SZ): The main product taurine has a wide range of applications and has been used in cosmetics

Gelonghui, Feb. 22 | Yongan Pharmaceutical (002365.SZ) said on the investor interactive platform that the company and its subsidiaries are mainly engaged in four types of business, one is R&D, production and sales of taurine products; the second is the production and sale of ethylene oxide and R&D, production and sales of related products such as polycarboxylic acid water reducing agent monomers, water reducing agents, etc.; the third is health food R&D, production and sales, and foreign health food imports and sales; four is equity or industrial investment related to the health sector, and the use of some idle funds for cash management, etc. The company's main product, taurine, has a wide range of applications and has been used in cosmetics;

Gelonghui FinanceFeb 22 16:58